8-K Announcements
6Material company update
Mar 12, 2026·SEC
Material company update
Nov 6, 2025·SEC
Material company update
Aug 7, 2025·SEC
Whitehawk Therapeutics Inc(WHWK)Earnings, Financials & Key Ratios
WHWK•NASDAQ
Price updated Jun 11, 2026
AboutWhitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.Show more
- Revenue$7M-72.5%
- EBITDA-$114M-70.1%
- Net Income-$21M+67.7%
- EPS (Diluted)-0.33+86.0%
- Gross Margin89.36%+182.7%
- EBITDA Margin-1601.12%-518.5%
- Operating Margin-1601.12%-516.7%
- Net Margin-288.26%-17.6%
- ROE-21.82%+73.0%
- ROIC-139.08%+6.2%
WHWK Key Insights
Whitehawk Therapeutics Inc (WHWK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 92 (top 8%)
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Profits declining 42.7% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Sales declining 13.3% over 5 years
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when WHWK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
WHWK Price & Volume
Whitehawk Therapeutics Inc (WHWK) stock price & volume — 10-year historical chart
Loading chart...
WHWK Growth Metrics
Whitehawk Therapeutics Inc (WHWK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-13.29%
3 Years-22.27%
TTM-72.5%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM67.66%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM120%
Return on Capital
10 Years-93.68%
5 Years-93.68%
3 Years-86.14%
Last Year-120.7%
WHWK Recent Earnings
Whitehawk Therapeutics Inc (WHWK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/6 qtrs (67%)
Q2 2026Latest
May 7, 2026EPS
$0.32
Est $0.36
+11.1%
Revenue
—
Q2 2026
Mar 12, 2026EPS
$0.34
Est $0.55
+38.2%
Revenue
—
Est $33M
Q4 2025
Nov 6, 2025EPS
$0.26
Est $0.51
+49.0%
Revenue
—
Est $25M
Q3 2025
Aug 7, 2025EPS
$0.76
Est $0.49
-255.1%
Revenue
—
Est $50M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.32vs $0.36+11.1% | — |
| Q2 2026 | Mar 12, 2026 | $0.34vs $0.55+38.2% | —vs $33M |
| Q4 2025 | Nov 6, 2025 | $0.26vs $0.51+49.0% | —vs $25M |
| Q3 2025 | Aug 7, 2025 | $0.76vs $0.49-255.1% | —vs $50M |
Based on last 6 quarters of dataView full earnings history →
WHWK Peer Comparison
Whitehawk Therapeutics Inc (WHWK) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.66B | 21.39 | 9.34 | 11.87% | 34.3% | 35.65% | 0.04 | |
 AXSM | 13.06B | 253.77 | -68.96 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INVA | 1.66B | 22.44 | 6.80 | 18.52% | 118.91% | 47.59% | 0.23 | |
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 NRXP | 67.76M | 3.92 | -2.93 | -10.7% | ||||
 ATAI | 1.4B | 3.80 | -1.31 | 12.28% | -190.19% | -366.21% | 0.01 | |
 CMPS | 1.1B | 11.41 | -3.70 | -151.02% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% |
Compare WHWK vs Peers
Whitehawk Therapeutics Inc (WHWK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
WHWK Income Statement
Whitehawk Therapeutics Inc (WHWK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 749K | 14.58M | 1.12M | 15.22M | 24.35M | 25.98M | 7.14M |
Revenue Growth % | - | 1846.6% | -92.32% | 1258.57% | 60.06% | 6.69% | -72.5% |
Cost of Goods Sold | 11.06M | 15.01M | 19.67M | 34M | 51.74M | 54.05M | 760K |
COGS % of Revenue | 1477.23% | 102.94% | 1756.25% | 223.43% | 212.44% | 208.04% | 10.64% |
Gross Profit | -10.32M▲ 0% | -428K▲ 95.9% | -18.55M▼ 4234.1% | -18.78M▼ 1.2% | -27.38M▼ 45.8% | -28.07M▼ 2.5% | 6.38M▲ 122.7% |
Gross Margin % | -1377.23% | -2.94% | -1656.25% | -123.43% | -112.44% | -108.04% | 89.36% |
Gross Profit Growth % | - | 95.85% | -4234.11% | -1.25% | -45.81% | -2.51% | 122.75% |
Operating Expenses | 1.85M | 2.12M | 92.67M | 43.9M | 44.55M | 39.39M | 120.78M |
OpEx % of Revenue | 247.58% | 14.55% | 8273.84% | 288.51% | 182.92% | 151.59% | 1690.48% |
Selling, General & Admin | 1.85M | 2.12M | 18.51M | 40.18M | 44.55M | 36.75M | 29.82M |
SG&A % of Revenue | 247.58% | 14.55% | 1652.77% | 264.04% | 182.92% | 141.43% | 417.38% |
Research & Development | 11.06M | 15.01M | 19.67M | 32.66M | 48.93M | 51.03M | 90.96M |
R&D % of Revenue | 1477.23% | 102.94% | 1756.25% | 214.66% | 200.91% | 196.4% | 1273.1% |
Other Operating Expenses | -11.06M | -15.01M | 54.49M | -28.94M | -48.93M | -48.39M | 0 |
Operating Income | -12.17M▲ 0% | -2.55M▲ 79.1% | -111.22M▼ 4263.2% | -62.68M▲ 43.6% | -71.93M▼ 14.8% | -67.46M▲ 6.2% | -114.4M▼ 69.6% |
Operating Margin % | -1624.81% | -17.48% | -9930.09% | -411.94% | -295.36% | -259.62% | -1601.12% |
Operating Income Growth % | - | 79.05% | -4263.16% | 43.64% | -14.76% | 6.22% | -69.59% |
EBITDA | -12.16M | -2.54M | -111.11M | -62.52M | -71.76M | -67.27M | -114.4M |
EBITDA Margin % | -1624.01% | -17.42% | -9920.71% | -410.9% | -294.67% | -258.88% | -1601.12% |
EBITDA Growth % | - | 79.12% | -4274.49% | 43.73% | -14.78% | 6.27% | -70.07% |
D&A (Non-Cash Add-back) | 5.98K | 9K | 105K | 159K | 169K | 193K | 0 |
EBIT | -12.17M | -2.55M | -37.06M | -58.96M | -71.93M | -64.82M | -114.4M |
Net Interest Income | -83.94K | -774K | -652K | 2.17M | 6.17M | 3.77M | 6.23M |
Interest Income | 0 | 41K | 13K | 2.4M | 6.4M | 3.92M | 6.23M |
Interest Expense | 83.94K | 815K | 665K | 230K | 231K | 154K | 0 |
Other Income/Expense | -83.94K | -927K | 1.13M | 2.17M | 6.17M | 3.77M | 93.8M |
Pretax Income | -12.25M▲ 0% | -3.48M▲ 71.6% | -110.09M▼ 3067.1% | -60.51M▲ 45.0% | -65.77M▼ 8.7% | -63.69M▲ 3.2% | -20.6M▲ 67.7% |
Pretax Margin % | -1636.02% | -23.84% | -9829.29% | -397.69% | -270.04% | -245.13% | -288.26% |
Income Tax | 1.3K | 2K | 2K | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.01% | -0.06% | -0% | 0% | 0% | 0% | 0% |
Net Income | -12.26M▲ 0% | -3.48M▲ 71.6% | -110.09M▼ 3065.3% | -60.51M▲ 45.0% | -65.77M▼ 8.7% | -63.69M▲ 3.2% | -20.6M▲ 67.7% |
Net Margin % | -1636.19% | -23.85% | -9829.46% | -397.69% | -270.04% | -245.13% | -288.26% |
Net Income Growth % | - | 71.62% | -3065.32% | 45.03% | -8.68% | 3.15% | 67.66% |
Net Income (Continuing) | -12.26M | -3.48M | -110.09M | -60.51M | -65.77M | -63.69M | -20.6M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.65▲ 0% | -0.21▲ 87.3% | -12.41▼ 5809.5% | -2.69▲ 78.3% | -2.44▲ 9.3% | -2.36▲ 3.3% | -0.33▲ 86.0% |
EPS Growth % | - | 87.27% | -5809.52% | 78.32% | 9.29% | 3.28% | 86.02% |
EPS (Basic) | -1.65 | -0.21 | -12.41 | -2.69 | -2.44 | -2.36 | -0.33 |
Diluted Shares Outstanding | 8.02M | 17.63M | 8.92M | 22.51M | 26.92M | 27.03M | 61.89M |
Basic Shares Outstanding | 7.42M | 20.84M | 8.87M | 22.51M | 26.92M | 27.03M | 61.89M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
WHWK Balance Sheet
Whitehawk Therapeutics Inc (WHWK) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
Total Current Assets | 16.31M | 18.68M | 151.27M | 180.03M | 124.59M | 61.29M | 149.01M |
Cash & Short-Term Investments | 15.96M | 4.46M | 148.99M | 172.56M | 108.84M | 47.24M | 145.7M |
Cash Only | 15.96M | 4.46M | 148.99M | 39.02M | 62.89M | 28.67M | 37.57M |
Short-Term Investments | 0 | 0 | 0 | 133.54M | 45.96M | 18.57M | 108.13M |
Accounts Receivable | 284.9K | 14.15M | 0 | 1.86M | 5.49M | 5.9M | 0 |
Days Sales Outstanding | 138.83 | 354.21 | - | 44.67 | 82.25 | 82.92 | - |
Inventory | 0 | 0 | 0 | 1.86M | 6.43M | 5.31M | 0 |
Days Inventory Outstanding | - | - | - | 19.98 | 45.34 | 35.86 | - |
Other Current Assets | 0 | 0 | 0 | 0 | 3.83M | 0 | 3.32M |
Total Non-Current Assets | 352.93K | 140K | 6.64M | 4.21M | 7.84M | 9.03M | 1.82M |
Property, Plant & Equipment | 315.97K | 140K | 614K | 2.03M | 5.97M | 7.63M | 3K |
Fixed Asset Turnover | 2.37x | 104.14x | 1.82x | 7.50x | 4.08x | 3.40x | 2381.67x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 3.81M | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 36.96K | 0 | 2.21M | 2.18M | 1.87M | 1.4M | 1.81M |
Total Assets | 16.66M▲ 0% | 18.82M▲ 13.0% | 157.91M▲ 738.8% | 184.24M▲ 16.7% | 132.42M▼ 28.1% | 70.32M▼ 46.9% | 150.83M▲ 114.5% |
Asset Turnover | 0.04x | 0.77x | 0.01x | 0.08x | 0.18x | 0.37x | 0.05x |
Asset Growth % | - | 13% | 738.83% | 16.67% | -28.12% | -46.9% | 114.49% |
Total Current Liabilities | 25.62M | 30.06M | 15.27M | 18.84M | 26.39M | 17.07M | 14.52M |
Accounts Payable | 3.18M | 2.39M | 6.44M | 3.52M | 5.9M | 2.16M | 917K |
Days Payables Outstanding | 104.82 | 58.17 | 119.48 | 37.78 | 41.61 | 14.58 | 440.4 |
Short-Term Debt | 8.16M | 9.03M | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 11.85M | 11.61M | 0 | 1.57M | 3.08M | 64K | 13.6M |
Current Ratio | 0.64x | 0.62x | 9.90x | 9.56x | 4.72x | 3.59x | 10.26x |
Quick Ratio | 0.64x | 0.62x | 9.90x | 9.46x | 4.48x | 3.28x | 10.26x |
Cash Conversion Cycle | - | - | - | 26.86 | 85.98 | 104.21 | - |
Total Non-Current Liabilities | 133.47K | 1.2M | 6.23M | 7.02M | 833K | 767K | 0 |
Long-Term Debt | 0 | 1.1M | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 133.47K | 0 | 474K | 1.27M | 833K | 565K | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 97K | 5.76M | 5.76M | 0 | 202K | 0 |
Total Liabilities | 25.75M | 31.26M | 21.5M | 25.86M | 27.23M | 17.84M | 14.52M |
Total Debt | 8.49M | 10.26M | 605K | 1.66M | 1.27M | 833K | 0 |
Net Debt | -7.48M | 5.8M | -148.38M | -37.36M | -61.62M | -27.84M | -37.57M |
Debt / Equity | - | - | 0.00x | 0.01x | 0.01x | 0.02x | - |
Debt / EBITDA | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - |
Interest Coverage | -144.99x | -3.13x | -55.73x | -256.33x | -311.40x | -420.91x | - |
Total Equity | -9.09M▲ 0% | -12.43M▼ 36.7% | 136.41M▲ 1197.2% | 158.38M▲ 16.1% | 105.19M▼ 33.6% | 52.48M▼ 50.1% | 136.31M▲ 159.7% |
Equity Growth % | - | -36.71% | 1197.22% | 16.11% | -33.58% | -50.11% | 159.75% |
Book Value per Share | -1.13 | -0.71 | 15.29 | 7.04 | 3.91 | 1.94 | 2.20 |
Total Shareholders' Equity | -9.09M | -12.43M | 136.41M | 158.38M | 105.19M | 52.48M | 136.31M |
Common Stock | 802 | 1K | 2K | 2K | 2K | 2K | 4K |
Retained Earnings | -29.12M | -32.59M | -142.69M | -203.2M | -268.96M | -332.65M | -353.25M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | -115K | 27K | 16K | 120K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
WHWK Cash Flow Statement
Whitehawk Therapeutics Inc (WHWK) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
Cash from Operations | -7.58M | -12.7M | -22.42M | -49.64M | -59.66M | -59.55M | -97.43M |
Operating CF Margin % | -1012.56% | -87.11% | -2002.05% | -326.24% | -244.98% | -229.19% | -1363.65% |
Operating CF Growth % | - | -67.47% | -76.55% | -121.38% | -20.19% | 0.19% | -63.62% |
Net Income | -12.26M | -3.48M | -110.09M | -60.51M | -65.77M | -63.69M | -20.6M |
Depreciation & Amortization | 5.98K | 9K | 105K | 159K | 169K | 193K | 0 |
Stock-Based Compensation | 106.14K | 139K | 2.11M | 9.64M | 11.95M | 10.84M | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 3.43M | 2.21M | 81.5M | 6.11M | -2.75M | -10.61M | -78.77M |
Working Capital Changes | 1.12M | -11.59M | 3.96M | -5.04M | -3.27M | 3.72M | 1.93M |
Change in Receivables | -39.7K | -13.86M | 14.15M | -1.86M | -3.63M | -415K | -1M |
Change in Inventory | 0 | 0 | 0 | -1.86M | -3.27M | 1.12M | 170K |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 3.92M |
Cash from Investing | -35.71K | 0 | 25.15M | -132.89M | 83.21M | 25.2M | 11.89M |
Capital Expenditures | -35.71K | 0 | -46K | -444K | -3.97M | -1.65M | -552K |
CapEx % of Revenue | 4.77% | - | 4.11% | 2.92% | 16.31% | 6.37% | 7.73% |
Acquisitions | 0 | 0 | 25.2M | 0 | 0 | 0 | 101.29M |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 8.07M | 1.19M | 141.8M | 72.62M | 326K | 130K | 94.38M |
Debt Issued (Net) | 8.07M | 1.19M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 155M | 72.5M | 0 | 130K | 100M |
Dividends Paid | 0 | 0 | -4.41M | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -8.78M | 120K | 326K | 0 | -5.63M |
Net Change in Cash | 15.96M▲ 0% | -11.51M▼ 172.1% | 144.53M▲ 1356.1% | -109.91M▼ 176.0% | 23.87M▲ 121.7% | -34.22M▼ 243.4% | 8.9M▲ 126.0% |
Free Cash Flow | -7.62M▲ 0% | -12.7M▼ 66.7% | -22.47M▼ 76.9% | -50.08M▼ 122.9% | -63.63M▼ 27.1% | -61.2M▲ 3.8% | -97.98M▼ 60.1% |
FCF Margin % | -1017.33% | -87.11% | -2006.16% | -329.15% | -261.29% | -235.55% | -1371.38% |
FCF Growth % | - | -66.68% | -76.91% | -122.9% | -27.06% | 3.82% | -60.1% |
FCF per Share | -0.95 | -0.72 | -2.52 | -2.22 | -2.36 | -2.26 | -1.58 |
FCF Conversion (FCF/Net Income) | 0.62x | 3.65x | 0.20x | 0.82x | 0.91x | 0.93x | 4.73x |
Interest Paid | 0 | 0 | 0 | 230K | 230K | 211K | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
WHWK Key Ratios
Whitehawk Therapeutics Inc (WHWK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -177.6% | -41.06% | -49.9% | -80.79% | -21.82% |
| Return on Invested Capital (ROIC) | - | - | - | -86.22% | -65.55% | -148.34% | -139.08% |
| Gross Margin | -1377.23% | -2.94% | -1656.25% | -123.43% | -112.44% | -108.04% | 89.36% |
| Net Margin | -1636.19% | -23.85% | -9829.46% | -397.69% | -270.04% | -245.13% | -288.26% |
| Debt / Equity | - | - | 0.00x | 0.01x | 0.01x | 0.02x | - |
| Interest Coverage | -144.99x | -3.13x | -55.73x | -256.33x | -311.40x | -420.91x | - |
| FCF Conversion | 0.62x | 3.65x | 0.20x | 0.82x | 0.91x | 0.93x | 4.73x |
| Revenue Growth | - | 1846.6% | -92.32% | 1258.57% | 60.06% | 6.69% | -72.5% |
Related:WHWK Dividend History·WHWK Revenue History·WHWK Price History·WHWK P/E History·WHWK Financial Ratios·WHWK Institutional Holders
WHWK SEC Filings & Documents
Whitehawk Therapeutics Inc (WHWK) SEC filings — annual & quarterly reports (10-K, 10-Q)
WHWK Frequently Asked Questions
Whitehawk Therapeutics Inc (WHWK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Whitehawk Therapeutics Inc (WHWK) reported $7.1M in revenue for fiscal year 2025. This represents a 854% increase from $0.7M in 2019.
Whitehawk Therapeutics Inc (WHWK) saw revenue decline by 72.5% over the past year.
Whitehawk Therapeutics Inc (WHWK) reported a net loss of $20.6M for fiscal year 2025.
Dividend & Returns
Whitehawk Therapeutics Inc (WHWK) has a return on equity (ROE) of -21.8%. Negative ROE indicates the company is unprofitable.
Whitehawk Therapeutics Inc (WHWK) had negative free cash flow of $98.0M in fiscal year 2025, likely due to heavy capital investments.